IGM Biosciences (IGMS) Stock Forecast & Price Target

$1.77 -0.06 (-3.28%)

As of 01/17/2025 04:00 PM Eastern

IGM Biosciences - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce

Based on 10 Analyst Ratings

Sell
1

Hold
9

Buy
0

Based on 10 Wall Street analysts who have issued ratings for IGM Biosciences in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 10 analysts, 1 has given a sell rating, and 9 have given a hold rating for IGMS.

Consensus Price Target

$5.50
210.73% Upside

According to the 10 analysts' twelve-month price targets for IGM Biosciences, the average price target is $5.50. The highest price target for IGMS is $20.00, while the lowest price target for IGMS is $1.50. The average price target represents a forecasted upside of 210.73% from the current price of $1.77.

Get the Latest News and Ratings for IGMS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IGM Biosciences and its competitors.

IGMS Analyst Ratings Over Time

Type	Current Forecast 1/21/24 to 1/20/25	1 Month Ago 12/22/23 to 12/21/24	3 Months Ago 10/23/23 to 10/22/24	1 Year Ago 1/21/23 to 1/21/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	5 Buy rating(s)	4 Buy rating(s)	3 Buy rating(s)
Hold	9 Hold rating(s)	2 Hold rating(s)	4 Hold rating(s)	6 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$5.50	$17.75	$15.00	$16.60
Forecasted Upside	210.73% Upside	157.25% Upside	-14.04% Downside	57.79% Upside
Consensus Rating	Reduce	Moderate Buy	Hold	Hold

IGMS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IGMS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

IGM Biosciences Stock vs. The Competition

Type	IGM Biosciences	Medical Companies	S&P 500
Consensus Rating Score	1.90	2.82	2.52
Consensus Rating	Reduce	Moderate Buy	Moderate Buy
Predicted Upside	210.73% Upside	24,741.16% Upside	12.44% Upside
News Sentiment Rating	Neutral News See Recent IGMS News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
1/13/2025	JPMorgan Chase & Co. 3 of 5 stars	Eric Joseph Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral
1/10/2025	Jefferies Financial Group 2 of 5 stars	Roger Song Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$48.00 ➝ $2.00	-5.21%
1/10/2025	Truist Financial 2 of 5 stars	A. Goonewardene Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Hold ➝ Hold	$12.00 ➝ $2.00	+3.09%
1/10/2025	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Driscoll Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Neutral	$22.00 ➝ $3.00	+53.06%
1/10/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Equal Weight ➝ Underweight	$12.00 ➝ $2.00	-67.74%
1/10/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Stephen Willey Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$27.00 ➝ $2.50	-59.68%
1/10/2025	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Abrahams Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$20.00 ➝ $1.50	-75.81%
1/10/2025	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Schmidt Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
1/10/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Darout Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$21.00 ➝ $2.00	-67.74%
9/5/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$12.00 ➝ $11.00	+5.77%
Get the Latest News and Ratings for IGMS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for IGM Biosciences and its competitors with MarketBeat's FREE daily newsletter.
12/15/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$8.00	+23.08%
8/7/2023	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold
8/7/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$31.00 ➝ $17.00	+87.64%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 07:55 PM ET.

IGMS Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for IGM Biosciences is $5.50, with a high forecast of $20.00 and a low forecast of $1.50.
: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IGM Biosciences in the last twelve months. There is currently 1 sell rating and 9 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "reduce" IGMS shares.
: According to analysts, IGM Biosciences's stock has a predicted upside of 210.73% based on their 12-month stock forecasts.
: Over the previous 90 days, IGM Biosciences's stock had 4 downgrades and 1 upgrade by analysts.
: IGM Biosciences has been rated by research analysts at BMO Capital Markets, Guggenheim, Jefferies Financial Group, JPMorgan Chase & Co., Morgan Stanley, Royal Bank of Canada, Stifel Nicolaus, Truist Financial, and Wedbush in the past 90 days.
: Analysts like IGM Biosciences less than other "medical" companies. The consensus rating for IGM Biosciences is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how IGMS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NASDAQ:IGMS) was last updated on 1/20/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IGM Biosciences (IGMS) Stock Forecast & Price Target